Abbott Laboratories $ 106.41 -1.2 (-1.12%)
Abbott Laboratories News and Headlines -
The firm reduced its stake in Microsoft Corp. (MSFT) by 84.19%. The trade had an impact of -1.18% on the portfolio.
The well-known tech company has a market cap of $1.60 trillion and an enterprise value of $1.53 trillion.
GuruFocus gives the company a profitability and growth rating of 9 out of 10. The return on equity of 41.49% and return on assets of 16.38% are outperforming 93% of companies
Abbott Laboratories (ABT)
Abbott Laboratories has been one of the most high-profile medical companies during 2020 thanks to their research on COVID-19 and their successful diagnostic tests. Abbott has released six different tests for COVID-19; four identify active infections and two are intended to identify past infection. Abbott has now sold over 40 million tests worldwide. The company has announced a new test called BinaxNOW which promises to deliver results in 15 minutes for as little as $5 per test. This test requires no special lab equipment, and its low cost could prove vital to widespread global testing as typical
The S&P 500 Index stocks saw their aggregate trailing 12-month revenue per share grow by approximately 4% on average every year over the past five years. The share price of the benchmark for the U.S. stock market ($3,400.97 as of Monday) has gained nearly 65% over the past five years through Oct. 26.
Thus, investors may want to consider the following stocks, as they have outperformed the S&P 500 index in terms of superior five-year revenue per share growth rates.
The first company that makes the cut is Visa Inc (V).
The San Francisco-based global provider of
Buying shares of companies trading well above off their average valuation and dividend yield can mean adding a stock with significant growth potential.
One of my favorite low multiple, high-yield stocks remains AbbVie Inc. (ABBV). The company's dividend track record and valuation show why this health care company should be consider by dividend growth and value investors alike.
Company background and historical performance
Spun off from parent company Abbott Laboratories (ABBV) in 2013, AbbVie is one of the largest pharmaceutical companies in the world. The company's products address illnesses and diseases such as rheumatoid arthritis, HIV, blood cancers, Crohn's disease
Teams from the Pac-10 and Big 10 conferences are returning to action safely, thanks in great part to Quidel Corp. (QDEL). Student athletes and staff personnel from member schools will be checked before every practice and every game for Covid-19 using the San Diego-based company's diagnostic test.
That news is welcome to not only the teams, but to investors as well. Year to date, Quidel shares have soared nearly 230% to $250. It appears the stock still has plenty of upside. Analysts rate Quidel a strong buy with a median target price of $361. Their bullishness is unquestionably tied to
According to the GuruFocus All-in-One Screener as of Sep. 10, the following healthcare stocks are popular among gurus.
Johnson & Johnson
Johnson & Johnson (JNJ) has a market cap of $391.21 billion. Its revenue of $80.5 billion has increased 2.90% over the past 10 years.
The company is held by 30 gurus, including Pioneer Investments (Trades, Portfolio) with 0.23% of outstanding shares, Jeremy Grantham (Trades, Portfolio) with 0.09% and Jim Simons (Trades, Portfolio)' Renaissance Technologies with 0.09%.
As of Sep. 10, the stock
A prominent Harvard epidemiologist and expert in disease testing thinks a cheap, daily, do-it-yourself test can be as effective as a vaccine at cutting coronavirus transmission, according to an article in the Harvard Gazette. Right now, such a test is the best bet for helping society return to some semblance of normal, said Michal Mina, assistant professor of epidemiology at Harvard T.H. Chan School of Public Health and Brigham and Women's Hospital.
One company seeking to provide a pair of tests that give instant results and can be done without equipment or a lab is OraSure Technologies Inc. (OSUR). The
The Dow Jones Industrial Average closed at 28,492.27 on Thursday with a gain of 160.35 points or 0.57%. The S&P 500 closed at 3,484.55 for a gain of 5.82 points or 0.17%. The Nasdaq Composite closed at 11,625.34 for a loss of 39.72 points or -0.34%. The VIX Volatility Index was higher at 24.47 for a gain of 1.20 points or 5.16%.
Thursday's Market Movers
The S&P 500 closed at another new high Thursday, but the Nasdaq ended lower. Financials and real estate led the day's gains. Semiconductors and consumer discretionary led losses.
Investors were watching a highly anticipated speech
U.S. stocks were in the green on Thursday morning, with the Dow advancing strong. The Dow gained more than 200 points to 28,570, the S&P 500 index gained 0.40% to 3,492 and the Nasdaq Composite Index was down 0.06% to 11,656.
The Federal Open Market Committee announced today that it has approved changes to its strategy, and in a statement, it said that it has adopted an "average inflation target" of "moderately" above 2% for "some time."
• Abbott Laboratories (ABT)
• Norwegian Cruise Line Holdings Ltd (NCLH)
• Carnival Corp (CCL)
• Delta Air Lines
Among the largest publicly traded pharmaceutical companies, Novo Nordisk (NVO) and Roche (RHHBY) had the highest returns on invested capital during the period from 2011 to 2019, according to a report from the Westhealth Policy Center. At the other end of the spectrum were Abbott Laboratories (ABT) and Easai Co. (TSE:4523).
In simplest terms, ROIC is a profitability ratio that indicates just how efficient a company is turning capital into profit. It measures the return that an investment generates for those who have provided capital (i.e., bondholders and stockholders).
ROIC can be important to investors because it is a key
Chicago-area pharmaceutical giant AbbVie Inc. (ABBV) is following the same winning strategy with its new cancer treatment that it did with its drug Humira, which is forecast to reach record-shattering cumulative sales of $240 billion by 2024.
Its plan? Build an impenetrable wall around the new Imbruvica, which is used to treat B cell cancers, via creative—some would say manipulative—use of the patent system.
AbbVie has become known as the master builder of patent walls, according to an article in Endpoints. “Its work on Humira has been both legendary and extraordinarily controversial, encircling a cash cow that can
The Dow Jones Industrial Average closed at 26,671.95 on Friday with a loss of 62.76 points or -0.23%. The S&P 500 closed at 3,224.73 for a gain of 9.16 points or 0.28%. The Nasdaq Composite closed at 10,503.19 for a gain of 29.36 points or 0.28%. The VIX Volatility Index was lower at 25.68 for a loss of 2.32 points or -8.29%.
For the week, the Dow Jones was up 2.3%, the S&P 500 was up 1.2% and the Nasdaq was down -1.1%. For the year, the Nasdaq has a gain of 16%, the S&P 500 is hovering around 0%
The portfolio that my wife and I are building has been publicly tracked since 2015 on a different platform. As this is the first posting of our portfolio’s performance on GuruFocus, I would like to give some background information about us and our investment goals and strategies.
Investment goals and strategies
We have nicknamed our portfolio “The March to Freedom” because we believe that investing is a long game and that there are no short-term solutions to creating a portfolio that can be used to pay for retirement.
Our portfolio consists of our Roth Individual Retirement Accounts and a workplace
Two leaders in the diabetes market are teaming up to provide a better way to administer insulin to patients.
Abbott Laboratories (ABT) and Tandem Diabetes Care Inc. (TNDM) have finalized an agreement to marry their respective continuous glucose monitors and digital insulin delivery systems, according to an article in FierceBiotech. The companies will also work together to market the system.
The announcement helped push the shares of San Diego-based Tandem to a one-year high of nearly $106, more than doubling its 52-week low.
Abbott’s stock is up several dollars since the partnership was announced, but it’s unlikely the deal drove
The Morgan Stanley Global Franchise Fund has released its first-quarter portfolio for 2020. Changes include new buys of Procter & Gamble Co. (PG) and LVMH Moet Hennessy Louis Vuitton SE (XPAR:MC), a sale of the existing Church & Dwight Co. Inc. (CHD) holding and additions to the Philip Morris International Inc. (PM) and Abbott Laboratories (ABT) positions.
The team follows a distinct and disciplined investment process based on bottom-up stock selection, with sector, industry and stock weightings driven by the team's assessment of each stock's quality and valuation characteristics. The team monitors signs of franchise abuse, including failing to
The Dow Jones Industrial Average closed at 25,445.94 on Wednesday with a loss of 710.16 points or -2.72%. The S&P 500 closed at 3,050.33 for a loss of 80.96 points or -2.59%. The Nasdaq Composite closed at 9,909.17 for a loss of 222.20 points or -2.19%. The VIX Volatility Index was higher at 33.75 for a gain of 2.38 points or 7.59%.
Wednesday’s market movers
Stocks sold off Wednesday with rising concerns over coronavirus infections. The seven-day infection count average increased 30% across the U.S. Texas, Florida, Arizona and California are showing some substantial increases. Florida and California set daily
Shareholders of Abbott Laboratories (ABT), Mastercard Inc (MA) and Lowe's Companies Inc (LOW) have seen their stocks return more than the S&P 500 index in recent years. The index increased by about 5.5% over the past year, 28% over the past three years and 48.5% over the past five years through June 23.
These stocks also hold positive recommendation ratings on Wall Street.
Shares of Abbott Laboratories have returned 8.4% over the past year, 86% over the past three years and 85% over the past five years through June 23, beating the S&P 500 by 2.7%, 58%
It can be difficult for investors to find undervalued stock with the S&P 500 trading at a price-earnings multiple near 23. For income investors, finding stocks with generous yields is also becoming tricky.
In this article, we will look at five high-yielding stocks that trade at a lower valuation than the S&P 500.
AbbVie Inc. (ABBV) was spun off from Abbot Laboratories (ABT) in 2013. The company’s Humira was the best-selling drug in the world for quite some time. Humira has lost patent protection in the European Union already and will do the same in the U.S. in
The Dow Jones Industrial Average closed at 26,281.82 on Thursday with a gain of 11.93 points or 0.05%. The S&P 500 closed at 3,112.35 for a loss of 10.52 points or -0.34%. The Nasdaq Composite closed at 9,615.81 for a loss of 67.10 points or -0.69%. The VIX Volatility Index was lower at 25.51 for a loss of 0.15 points or -0.58%.
Thursday’s market movers
U.S. indexes ended mostly lower Thursday after a four-day rally. Applications for jobless claims decreased from the previous week, but still remained extremely high at 1.877 million. The number of Americans receiving unemployment benefits also
Bridgewater Associates, the $165 billion hedge fund founded by Ray Dalio (Trades, Portfolio), disclosed this week that its top five buys for the first quarter were McDonald’s Corp. (MCD), UnitedHealth Group Inc. (UNH), Lockheed Martin Corp. (LMT), Phillip Morris International Inc. (PM) and Abbott Laboratories (ABT).
Dalio, co-chief investment officer of Bridgewater, started the Greenwich, Connecticut-based fund in 1975. According to his LinkedIn profile, Dalio invented “industry-changing” approaches to investing, which include the invention of risk parity, currency overlay and portable alpha. The Bridgewater co-chief investment officer listed several key principles in his book “Principles: Life and